The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing ...

Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new Novartis drug and two biotechs cut staff.

The Italian drugmaker will pay as much as $115 million in upfront and near-term payments in a deal that gives it rights to a ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional antibodies that can hit two or more targets at once.